尿激酶与低分子肝素联合对急性肺动脉栓塞的临床疗效研究

Clinical Effect of Urokinase Combined with Low Molecular Weight Heparin on Acute Pulmonary Embolism

目的:探讨采用尿激酶与低分子肝素联合治疗对急性肺动脉栓塞患者的临床疗效。方法:选取笔者所在医院2016年1月-2019年6月收治的急性肺动脉栓塞患者96例为研究对象,采用随机数字表法将患者分成研究组(给予尿激酶联合低分子肝素治疗)和对照组(给予低分子肝素联合华法林钠治疗),每组48例。对比两组临床疗效及治疗前后动脉血气、肺损伤指标。结果:治疗后研究组PaO2、P(A-a)O2和t-PA、TM均优于对照组,差异均有统计学意义(P<0.05)。研究组治疗总有效率为91.67%,高于对照组的75.00%,差异有统计学意义(P<0.05)。结论:采用尿激酶与低分子肝素联合治疗急性肺动脉栓塞能够有效改善患者动脉血气和肺损伤情况,显著提升临床综合疗效,是临床治疗急性肺动脉栓塞的可靠方案。

Objective:To investigate the clinical efficacy of Urokinase combined with Low Molecular Weight Heparin in the treatment of acute pulmonary embolism.Method:From January 2016 to June 2019,96 patients with acute pulmonary embolism admitted to our hospital were selected as the research objects.The patients were randomly divided into the study group (treated with Urokinase combined with Low Molecular Weight Heparin) and the control group (treated with Low Molecular Weight Heparin and Warfarin Sodium),48 cases in each group.The clinical efficacy and indexes of arterial blood gas and lung injury before and after treatment were compared between the two groups.Result:After treatment,PaO2,P (A-a)O2,t-PA and TM in the study group were all better than those in the control group,the differences were statistically significant (P<0.05).The total effective rate of treatment in the study group was 91.67%,higher than 75.00% in the control group,the difference was statistically significant (P<0.05).Conclusion:Urokinase combined with Low Molecular Weight Heparin in treatment of acute pulmonary embolism can effectively improve the arterial blood gas and lung injury,significantly improve the clinical comprehensive efficacy.It is one of the reliable clinical treatment of acute pulmonary embolism.